Interphex

Patheon (Booth 1424) has signed a strategic agreement with Grünenthal, a research-based pharmaceutical group based in Germany, to serve as its preferred development partner for its products using Grünenthal’s abuse deterrent formulation technology INTAC.

Patheon will assist with the development of advanced INTAC-based products including single-entity and fixed-dose combination solid oral dosage forms with immediate and modified release properties. Grünenthal will install specialized equipment in Patheon’s Cincinnati manufacturing site, allowing clients to benefit from Patheon’s process, staff and infrastructure designed to simplify manufacturing.

“This agreement is a tangible example of the deeper, collaborative relationships we are pursuing and winning with clients,” said Mike Lehmann, executive vice president, global sales and marketing, Patheon. “Over the past several years we have built a business to meet the needs of a breadth of clients – from emerging pharma companies to large multinationals.”

Dr. Klaus-Dieter Langner, chief scientific officer Grünenthal Group said, “It is recognized in the healthcare industry that prescription drug abuse is an issue of growing concern in the U.S. Typically it is opioids, CNS depressants and stimulants that are the three most established drug classes that are abused. Novel formulation technologies will help reduce that abuse potential.”